

# Oliver Wirths

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4366058/publications.pdf>

Version: 2024-02-01

116  
papers

6,944  
citations

53794

45  
h-index

62596

80  
g-index

131  
all docs

131  
docs citations

131  
times ranked

7336  
citing authors

#	ARTICLE	IF	CITATIONS
1	Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal A $\beta$ aggregation in the 5XFAD mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 196.e29-196.e40.	3.1	421
2	Massive CA1/2 Neuronal Loss with Intraneuronal and N-Terminal Truncated A $\beta$ <sup>242</sup> Accumulation in a Novel Alzheimer Transgenic Model. <i>American Journal of Pathology</i> , 2004, 165, 1289-1300.	3.8	375
3	A modified A $\beta$ -amyloid hypothesis: intraneuronal accumulation of the A $\beta$ -amyloid peptide "the first step of a fatal cascade. <i>Journal of Neurochemistry</i> , 2004, 91, 513-520.	3.9	344
4	Intraneuronal A $\beta$ accumulation precedes plaque formation in A $\beta$ -amyloid precursor protein and presenilin-1 double-transgenic mice. <i>Neuroscience Letters</i> , 2001, 306, 116-120.	2.1	323
5	Time sequence of maturation of dystrophic neurites associated with A $\beta$ deposits in APP/PS1 transgenic mice. <i>Experimental Neurology</i> , 2003, 184, 247-263.	4.1	257
6	Hippocampal Neuron Loss Exceeds Amyloid Plaque Load in a Transgenic Mouse Model of Alzheimer's Disease. <i>American Journal of Pathology</i> , 2004, 164, 1495-1502.	3.8	233
7	Pyroglutamate Amyloid-A $\beta$ (A $\beta$ ): A Hatchet Man in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2011, 286, 38825-38832.	3.4	177
8	Intracellular accumulation of amyloid-beta "a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2010, 2, 8.	3.4	161
9	Key Factors in Alzheimer's Disease: A $\beta$ -Amyloid Precursor Protein Processing, Metabolism and Intraneuronal Transport. <i>Brain Pathology</i> , 2001, 11, 1-11.	4.1	159
10	N-truncated amyloid A $\beta$ (A $\beta$ ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. <i>Acta Neuropathologica</i> , 2013, 126, 189-205.	7.7	153
11	Intraneuronal pyroglutamate-A $\beta$ 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. <i>Acta Neuropathologica</i> , 2009, 118, 487-496.	7.7	151
12	Overexpression of Human Dickkopf-1, an Antagonist of wingless/WNT Signaling, in Human Hepatoblastomas and Wilms' Tumors. <i>Laboratory Investigation</i> , 2003, 83, 429-434.	3.7	134
13	Focusing the amyloid cascade hypothesis on N-truncated A $\beta$ peptides as drug targets against Alzheimer's disease. <i>Acta Neuropathologica</i> , 2014, 127, 787-801.	7.7	129
14	Transient intraneuronal A $\beta$ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. <i>Acta Neuropathologica</i> , 2008, 116, 647-655.	7.7	116
15	Intraneuronal APP/A $\beta$ Trafficking and Plaque Formation in A $\beta$ -Amyloid Precursor Protein and Presenilin-1 Transgenic Mice. <i>Brain Pathology</i> , 2002, 12, 275-286.	4.1	113
16	Axonopathy in an APP/PS1 transgenic mouse model of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2006, 111, 312-319.	7.7	113
17	Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2010, 31, 747-757.	3.1	111
18	Age-dependent axonal degeneration in an Alzheimer mouse model. <i>Neurobiology of Aging</i> , 2007, 28, 1689-1699.	3.1	107

#	ARTICLE	IF	CITATIONS
19	Glycoprotein NMB: a novel Alzheimer's disease associated marker expressed in a subset of activated microglia. <i>Acta Neuropathologica Communications</i> , 2018, 6, 108.	5.2	107
20	Histone Deacetylase Inhibitor Valproic Acid Inhibits Cancer Cell Proliferation via Down-regulation of the Alzheimer Amyloid Precursor Protein. <i>Journal of Biological Chemistry</i> , 2010, 285, 10678-10689.	3.4	104
21	Accumulation of intraneuronal A $\beta$ 2 correlates with ApoE4 genotype. <i>Acta Neuropathologica</i> , 2010, 119, 555-566.	7.7	94
22	Identification of Low Molecular Weight Pyroglutamate A $\beta$ 2 Oligomers in Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2010, 285, 41517-41524.	3.4	91
23	Effects of Long-Term Environmental Enrichment on Anxiety, Memory, Hippocampal Plasticity and Overall Brain Gene Expression in C57BL6 Mice. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 62.	2.9	88
24	Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. <i>Journal of Neural Transmission</i> , 2010, 117, 85-96.	2.8	87
25	Phosphorylation of the amyloid $\beta$ -peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity. <i>Acta Neuropathologica</i> , 2016, 131, 525-537.	7.7	84
26	Motor impairment in Alzheimer's disease and transgenic Alzheimer's disease mouse models. <i>Genes, Brain and Behavior</i> , 2008, 7, 1-5.	2.2	81
27	Intraneuronal A $\beta$ 2 accumulation and neurodegeneration: Lessons from transgenic models. <i>Life Sciences</i> , 2012, 91, 1148-1152.	4.3	81
28	Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1223-1236.	2.6	80
29	Overexpression of Glutamyl Cyclase, the Enzyme Responsible for Pyroglutamate A $\beta$ 2 Formation, Induces Behavioral Deficits, and Glutamyl Cyclase Knock-out Rescues the Behavioral Phenotype in 5XFAD Mice. <i>Journal of Biological Chemistry</i> , 2011, 286, 4454-4460.	3.4	79
30	Early intraneuronal accumulation and increased aggregation of phosphorylated Abeta in a mouse model of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2013, 125, 699-709.	7.7	79
31	Deciphering the Molecular Profile of Plaques, Memory Decline and Neuron Loss in Two Mouse Models for Alzheimer's Disease by Deep Sequencing. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 75.	3.4	78
32	Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008, 29, 891-901.	3.1	75
33	APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. <i>Acta Neuropathologica</i> , 2009, 117, 677-685.	7.7	74
34	Pyroglutamate Amyloid $\beta$ 2 (A $\beta$ 2) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2012, 287, 8154-8162.	3.4	71
35	Environmental enrichment fails to rescue working memory deficits, neuron loss, and neurogenesis in APP/PS1KI mice. <i>Neurobiology of Aging</i> , 2012, 33, 96-107.	3.1	71
36	OTX1 and OTX2 Expression Correlates With the Clinicopathologic Classification of Medulloblastomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 176-186.	1.7	68

#	ARTICLE	IF	CITATIONS
37	Traumatic brain injury: cause or risk of Alzheimer's disease? A review of experimental studies. <i>Journal of Neural Transmission</i> , 2005, 112, 1547-1564.	2.8	67
38	Intracellular A $\beta$ triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2010, 31, 1153-1163.	3.1	66
39	Physical activity delays hippocampal neurodegeneration and rescues memory deficits in an Alzheimer disease mouse model. <i>Translational Psychiatry</i> , 2016, 6, e800-e800.	4.8	64
40	Neprilysin Deficiency Alters the Neuropathological and Behavioral Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 1291-1302.	2.6	63
41	Neuron Loss in Transgenic Mouse Models of Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-6.	2.0	57
42	Reelin in plaques of $\beta$ -amyloid precursor protein and presenilin-1 double-transgenic mice. <i>Neuroscience Letters</i> , 2001, 316, 145-148.	2.1	55
43	Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2564-2573.	3.1	55
44	Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. <i>Journal of Neural Transmission</i> , 2008, 115, 1651-1659.	2.8	52
45	Review on the APP/PS1KI mouse model: intraneuronal A $\beta$ accumulation triggers axonopathy, neuron loss and working memory impairment. <i>Genes, Brain and Behavior</i> , 2008, 7, 6-11.	2.2	47
46	Lewy body variant of Alzheimer's disease. <i>NeuroReport</i> , 2000, 11, 3737-3741.	1.2	46
47	Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2007, 114, 387-394.	2.8	44
48	The metalloprotease ADAMTS4 generates N-truncated A $\beta$ species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 239-257.	7.7	44
49	Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 243-250.	2.6	40
50	Altered neurogenesis in mouse models of Alzheimer disease. <i>Neurogenesis (Austin, Tex)</i> , 2017, 4, e1327002.	1.5	39
51	A two-step immunoassay for the simultaneous assessment of A $\beta$ <sub>38</sub> , A $\beta$ <sub>40</sub> and A $\beta$ <sub>42</sub> in human blood plasma supports the A $\beta$ <sub>42</sub> /A $\beta$ <sub>40</sub> ratio as a promising biomarker candidate of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 121.	6.2	39
52	Neuron Loss in Alzheimer's Disease: Translation in Transgenic Mouse Models. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8144.	4.1	39
53	The Arctic A $\beta$ PP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated A $\beta$ . <i>Acta Neuropathologica Communications</i> , 2013, 1, 60.	5.2	38
54	No alterations of hippocampal neuronal number and synaptic bouton number in a transgenic mouse model expressing the $\beta$ -cleaved C-terminal APP fragment. <i>Neurobiology of Disease</i> , 2003, 12, 110-120.	4.4	37

#	ARTICLE	IF	CITATIONS
55	N-truncated Aβ starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. <i>Acta Neuropathologica Communications</i> , 2013, 1, 56.	5.2	36
56	Î±-Synuclein, Aβ and Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 103-108.	4.8	35
57	Concomitant detection of Î²-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice. <i>Journal of Chemical Neuroanatomy</i> , 2010, 40, 82-92.	2.1	34
58	Limited Effects of Prolonged Environmental Enrichment on the Pathology of 5XFAD Mice. <i>Molecular Neurobiology</i> , 2017, 54, 6542-6555.	4.0	34
59	N-truncated Aβ <sub>24</sub> peptides in sporadic Alzheimer's disease cases and transgenic Alzheimer mouse models. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 80.	6.2	34
60	Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology?. <i>Biochemical Society Transactions</i> , 2011, 39, 857-861.	3.4	33
61	Aβ <sub>25-35</sub> Accumulation and/or Intraneuronal Amyloid-β Accumulation? The 3xTg-AD Mouse Model Revisited. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 897-904.	2.6	33
62	No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 833.e39-833.e50.	3.1	32
63	Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 991-1004.	3.4	32
64	Formic acid is essential for immunohistochemical detection of aggregated intraneuronal Aβ peptides in mouse models of Alzheimer's disease. <i>Brain Research</i> , 2009, 1301, 116-125.	2.2	31
65	Deposition of C-terminally truncated Aβ species Aβ <sub>23-37</sub> and Aβ <sub>23-39</sub> in Alzheimer's disease and transgenic mouse models. <i>Acta Neuropathologica Communications</i> , 2016, 4, 24.	5.2	29
66	The Cannabinoid CB1/CB2 Agonist WIN55212.2 Promotes Oligodendrocyte Differentiation In Vitro and Neuroprotection During the Cuprizone-Induced Central Nervous System Demyelination. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 387-395.	3.9	29
67	A microRNA signature that correlates with cognition and is a target against cognitive decline. <i>EMBO Molecular Medicine</i> , 2021, 13, e13659.	6.9	29
68	Immunochemical-induced loss of cholinergic projection neurones promotes Aβ amyloidosis and tau hyperphosphorylation in the hippocampus of triple transgenic mice. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 106-120.	3.2	28
69	Axonal degeneration in an Alzheimer mouse model is PS1 gene dose dependent and linked to intraneuronal Aβ accumulation. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 139.	3.4	26
70	Endogenous Apolipoprotein E (ApoE) Fragmentation Is Linked to Amyloid Pathology in Transgenic Mouse Models of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2017, 54, 319-327.	4.0	26
71	Aβ <sub>28-38</sub> in the Brains of Patients with Sporadic and Familial Alzheimer's Disease and Transgenic Mouse Models. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 871-881.	2.6	25
72	Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2011, 32, 1379-1387.	3.1	23

#	ARTICLE	IF	CITATIONS
73	Loss of Hippocampal Calretinin and Parvalbumin Interneurons in the 5XFAD Mouse Model of Alzheimer's Disease. <i>ASN Neuro</i> , 2020, 12, 175909142092535.	2.7	23
74	Circulating immune complexes of A $\beta$ and IgM in plasma of patients with Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2009, 116, 913-920.	2.8	22
75	Chronic Memantine Treatment Ameliorates Behavioral Deficits, Neuron Loss, and Impaired Neurogenesis in a Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2021, 58, 204-216.	4.0	22
76	N-terminal heterogeneity of parenchymal and vascular amyloid $\beta$ deposits in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 673-685.	3.2	20
77	Abundance of A $\beta$ <sub>25</sub> -like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 13.	10.8	19
78	Long-term caffeine treatment of Alzheimer mouse models ameliorates behavioural deficits and neuron loss and promotes cellular and molecular markers of neurogenesis. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 1.	5.4	19
79	Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. <i>Experimental Gerontology</i> , 2006, 41, 220-224.	2.8	18
80	Age-dependent loss of dentate gyrus granule cells in APP/PS1KI mice. <i>Brain Research</i> , 2008, 1222, 207-213.	2.2	18
81	Intraneuronal A $\beta$ -Amyloid Is a Major Risk Factor – Novel Evidence from the APP/PS1KI Mouse Model. <i>Neurodegenerative Diseases</i> , 2008, 5, 140-142.	1.4	18
82	Oligomeric Pyroglutamate Amyloid $\beta$ is Present in Microglia and a Subfraction of Vessels in Patients with Alzheimer's Disease: Implications for Immunotherapy. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 741-749.	2.6	18
83	Antibody 9D5 Recognizes Oligomeric Pyroglutamate Amyloid $\beta$ in a Fraction of Amyloid $\beta$ Deposits in Alzheimer's Disease without Cross-Reactivity with other Protein Aggregates. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 361-371.	2.6	17
84	Interferon-driven brain phenotype in a mouse model of RNaseT2 deficient leukoencephalopathy. <i>Nature Communications</i> , 2021, 12, 6530.	12.8	16
85	Abundant pyroglutamate-modified A $\beta$ <sub>1-42</sub> and A $\beta$ <sub>1-40</sub> peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias. <i>Neurobiology of Aging</i> , 2013, 34, 1416-1425.	3.1	14
86	I716F A $\beta$ <sub>23-42</sub> Mutation Associates with the Deposition of Oligomeric Pyroglutamate Amyloid $\beta$ and $\alpha$ -Synucleinopathy with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 103-114.	2.6	13
87	Amyloid Precursor Protein Is a Biomarker for Transformed Human Pluripotent Stem Cells. <i>American Journal of Pathology</i> , 2012, 180, 1636-1652.	3.8	12
88	Gene Expression Profiling in the APP/PS1KI Mouse Model of Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 397-409.	2.6	12
89	Physical Activity Ameliorates Impaired Hippocampal Neurogenesis in the Tg4-42 Mouse Model of Alzheimer's Disease. <i>ASN Neuro</i> , 2019, 11, 175909141989269.	2.7	12
90	Development and Technical Validation of an Immunoassay for the Detection of APP669-711 (A $\beta$ <sub>3-40</sub> ) in Biological Samples. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6564.	4.1	12

#	ARTICLE	IF	CITATIONS
91	Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 94.	6.2	12
92	Synergistic Effect on Neurodegeneration by N-Truncated A $\beta$ <sup>24-42</sup> and Pyroglutamate A $\beta$ <sup>23-42</sup> in a Mouse Model of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 64.	3.4	11
93	N-Terminal Truncated A $\beta$ <sup>24-42</sup> Is a Substrate for Neprilysin Degradation <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Alzheimer's Disease</i> , 2019, 67, 849-858.	2.6	10
94	Preparation of Crude Synaptosomal Fractions from Mouse Brains and Spinal Cords. <i>Bio-protocol</i> , 2017, 7, e2423.	0.4	10
95	N-Truncated A $\beta$ <sup>22-X</sup> Starting with Position Two in Sporadic Alzheimer's Disease Cases and Two Alzheimer Mouse Models. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 101-110.	2.6	9
96	The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 62.	5.2	9
97	Physical activity and cognitive stimulation ameliorate learning and motor deficits in a transgenic mouse model of Alzheimer's disease. <i>Behavioural Brain Research</i> , 2021, 397, 112951.	2.2	7
98	Characterization of a Mouse Model of Alzheimer's Disease Expressing A $\beta$ <sup>24-42</sup> and Human Mutant Tau. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5191.	4.1	7
99	Altered cholesterol metabolism in APP695-transfected neuroblastoma cells. <i>Brain Research</i> , 2007, 1152, 209-214.	2.2	6
100	Detection and quantification of A $\beta$ <sup>23-40</sup> (APP669 $\beta$ 11) in cerebrospinal fluid. <i>Journal of Neurochemistry</i> , 2022, 160, 578-589.	3.9	6
101	N-Terminally Truncated A $\beta$ Peptide Variants in Alzheimer's Disease. , 0, , 107-122.		5
102	The anti-parallel dimer binding interface in STAT3 transcription factor is required for the inactivation of cytokine-mediated signal transduction. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 119118.	4.1	4
103	Extraction of Soluble and Insoluble Protein Fractions from Mouse Brains and Spinal Cords. <i>Bio-protocol</i> , 2017, 7, e2422.	0.4	4
104	Immunotherapy Against N-Truncated Amyloid- $\beta$ Oligomers. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 37-50.	0.2	3
105	Immunotherapy Targeting Amyloid- $\beta$ Peptides in Alzheimer's Disease. , 0, , 23-49.		3
106	Mepri $\beta$ knockout reduces brain A $\beta$ levels and rescues learning and memory impairments in the APP/lon mouse model for Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 168.	5.4	3
107	Early Intraneuronal $\beta$ -Amyloid Pathology: Do Transgenic Mice Represent Valid Model Systems?. <i>The Open Aging Journal</i> , 2008, 2, 7-12.	0.0	2
108	Combined long-term enriched environment and caffeine supplementation improve memory function in C57Bl6 mice. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 0, , .	3.2	2

#	ARTICLE	IF	CITATIONS
109	An inhibitory effect on the nuclear accumulation of phospho-STAT1 by its unphosphorylated form. <i>Cell Communication and Signaling</i> , 2022, 20, 42.	6.5	1
110	Die modifizierte Amyloid-Hypothese der Alzheimer-Demenz – intraneuronales Abeta induziert Neurodegeneration. <i>E-Neuroforum</i> , 2009, 15, 76-83.	0.1	0
111	Problems During Aging (Alzheimer’s and Others). , 2013, , 2953-2969.		0
112	Early Intraneuronal $\beta$ -Amyloid Pathology: Do Transgenic Mice Represent Valid Model Systems?. <i>Open Longevity Science</i> , 2008, 2, 7-12.	0.8	0
113	Immunocytochemical Detection of Intraneuronal $A\beta$ Peptides in Mouse Models of Alzheimer’s Disease. <i>Neuromethods</i> , 2015, , 179-193.	0.3	0
114	Physical activity ameliorates neuron loss and memory deficits in Tg4-42 mice. <i>Pharmacopsychiatry</i> , 2015, 48, .	3.3	0
115	Physical activity ameliorates neuron loss and memory deficits in Tg4-42 mice. <i>Pharmacopsychiatry</i> , 2015, 48, .	3.3	0
116	Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor. <i>BMC Molecular and Cell Biology</i> , 2022, 23, .	2.0	0